GDUFA IV commitments: New onshoring incentives and meeting types for generic drugs

RegulatoryNeutral

AI Analysis

Summary

FDA announces GDUFA IV commitments for 2028-2032 period including new onshoring incentives and meeting types for generic drug applicants, maintaining similar review timelines as the previous five years.

Outcome Details

GDUFA IV commitments for 2028-2032 period establishing new onshoring incentives and meeting types for generic drug applications

Importance:2/10

Sentiment:

0.00

generic_drugsFDAGDUFAonshoringmanufacturingregulatory

Related Companies

$DMAA

Read the original article

Published by Endpoints News on August 12, 2026 5:26 PM

Read Original